ArticleCancer research communications2024

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

Mark Yarchoan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.